Germany`s CureVac has made an announcement on Monday that it has enrolled the first participant in the Phase 2b/3 study of its COVID-19 vaccine candidate. The safety and efficacy in adults will be assessed in the trial and more than 35,000 participants in Europe and Latin America were expected to be included in the trial, the Company statement added. 

“With the start of the pivotal Phase 2b/3 study, we have reached another important milestone in the development of our vaccine candidate, CVnCoV,” Franz-Werner Haas, the CEO of CureVac, said in a statement on Monday. Phase 3 results are expected to be out by March 2021. CureVac has begun the development of its mRNA-based Covid-19 vaccine candidate last January. The previous studies reveal that the newly developed vaccine was “generally well tolerated across all tested doses and induced strong antibody responses,” the company statement reads. ”The quality of immune response was comparable to recovered Covid-19 patients, closely mimicking the immune response after natural Covid-19 infection.”

Another German company  vaccine candidate based on mRNA technology, BioNTech, helped develop the first vaccine approved for use in the United States, together with US company Pfizer and in few other countries including UK which has already rolled out the vaccine. The native country which is to shut for the Christmas due to increased Corona cases has not approved any vaccine candidate for its people yet. 

DCGI gives approval to India's first indigenous mRNA vaccine for human trial

Australia Stops COVID-19 Vaccine Trials Due To HIV Antibody Positives

Glenmark the first company to receive approval DCGI to conduct clinical trials